PA
SRPT icon

PFG Advisors’s Sarepta Therapeutics SRPT Stock Holding History

PFG Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,313
Closed -$403K – 717
2024
Q4 		$403K Sell
3,313
-57
-2% -$6.99K 0.02% 511
2024
Q3 		$421K Hold
3,370
– – 0.03% 497
2024
Q2 		$532K Sell
3,370
-1,198
-26% -$154K 0.04% 409
2024
Q1 		$591K Buy
+4,568
New +$560K 0.04% 360

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PFG Advisors's SRPT Position: Q1 2025 in Review

PFG Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 3,313 shares — an estimated $403K sold.

PFG Advisors first reported a position in SRPT in Q1 2024 and held it in 4 quarters. The position peaked at $591K in Q1 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • PFG Advisors reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PFG Advisors sold 3,313 Sarepta Therapeutics shares in Q1 2025, an estimated $403K.
  • PFG Advisors first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 4 quarters.
  • PFG Advisors's Sarepta Therapeutics position peaked at $591K in Q1 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on PFG Advisors's 13F filing for Q1 2025, filed 6 May 2025.